

Title Page

The Pore-Lipid interface: Role of Amino Acid Determinants of Lipophilic Access by Ivabradine to the hERG1 Pore Domain

Laura Perissinotti,^{1†} Jiqing Guo,^{2†} Meruyert Kudaibergenova,^{1†} James Lees-Miller², Marina Ol'khovich³, Angelica Sharapova³, German L. Perlovich³, Daniel A Muruve⁴, Brenda Gerull⁵,
Sergei Yu. Noskov^{1*} and Henry J. Duff^{2*}

1. Centre for Molecular Simulation, Department of Biological Sciences, University of Calgary, Calgary, AB, Canada
2. Libin Cardiovascular Institute of Alberta, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
3. Institute of Solution Chemistry, Russian Academy of Sciences, 1 Akademicheskaya Street, 153045, Ivanovo, Russian Federation
4. Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
5. Department of Cardiac Sciences and Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada, Comprehensive Heart Failure Center and Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany

† These authors contributed equally to this work

*Corresponding Authors:

* H.J. Duff, M.D., Professor; University of Calgary, Cumming School of Medicine, Libin Institute, HRIC GC73, 3280 Hospital Drive NW; Calgary, Alberta, Canada T2N 4Z6 e-mail: hduff@ucalgary.ca

* S.Yu. Noskov, Ph.D., Professor, Department of Biological Sciences; University of Calgary 2500 University Drive, Alberta, Canada, T2N 1N4; e-mail: snoskov@ucalgary.ca

Running Title Page

hERG1, Blockade, Lipophilic access, Allostery, Ivabradine

Non-Standard Abbreviations:

hERG1: The **H**uman *E*ther-*à*-*g*o-*g*o-**R**elated **G**ene in reference to alpha-subunit of Kv11.1 K⁺ channel.

hEAG1: Human Ether à Go-Go 1 Gene in reference to alpha-subunit of Kv10.1 K⁺ channel.

TM: **T**rans-**M**embrane

PD: **P**ore-**D**omain

VSD: **V**oltage-**S**ensing-**D**omain

PAS: **P**er-**A**rnst-**S**im **D**omain

CNBD: **C**yclic-**N**ucleotide-**B**inding **D**omain

WT: **W**ild-**T**ype

MD: **M**olecular **D**ynamics

HEK 293 or HEK: **H**uman **E**mbryonic **K**idney 293 cells

Abstract

Abnormal cardiac electrical activity is a common side effect caused by unintended block of the promiscuous drug target hERG1; the pore-forming domain of the delayed rectifier K⁺ channel in the heart. hERG1 block leads to a prolongation of the QT interval, a phase of the cardiac cycle that underlies myocyte repolarization which is detectable on the ECG. Even newly released drugs, such as heart-rate lowering agent - ivabradine, block the *I_{Kr}*, prolong action potential duration (APD) and induce potentially lethal arrhythmia known as Torsades de Pointes (*TdP*). In this study, we describe a critical drug-binding pocket located at the lateral pore surface facing the cellular membrane. Mutations of the conserved M651 residue alter ivabradine induced block but not by the common hERG1 blocker, dofetilide. As revealed by MD simulations, binding of ivabradine to a lipophilic pore access site is coupled to a state-dependent reorientation of aromatic residues F557 and F656 in the S5 and S6 helices. We show that the M651 mutation impedes state-dependent dynamics of F557 and F656 aromatic cassette at the protein-lipid interface which has a potential to disrupt drug induced block of the channel. This fundamentally new mechanism coupling the channel dynamics and small-molecule access from the membrane into the hERG1 intra-cavitary site provides a simple rationale for the well-established state-dependence of drug blockade.

INTRODUCTION

The cardiac action potential is primarily generated by sodium and calcium channels, which depolarize the membrane potential, and by potassium channels that repolarize the membrane potential and terminate the Action Potential (AP) (Nerbonne and Kass, 2005). Gene mutations, age-related factors and drug-induced toxicity are all linked to various perturbation of APs, leading to potential lethal disorders of heart rhythms (arrhythmias) (Chiamvimonvat et al., 2017). Several K⁺ selective channels were identified as major determinants of pro-arrhythmic activity and main targets for anti-arrhythmic drug development. Perhaps the most impactful of these is the human ether-a-go-go related gene 1 (hERG1 or Kv11.1) channel, the K⁺ selective channel carrying the rapid delayed rectifier current (I_{Kr}) in myocytes (Trudeau et al., 1995). The physiological role of I_{Kr} is to repolarize the late phase of cardiac action potential, hence currents carried by hERG1 that contain human mutations are linked to arrhythmias (Gustina and Trudeau, 2009; Vandenberg et al., 2012). Similarly, pharmacological blockage of the I_{Kr} can lead to a prolongation of the QT interval (phase 3 repolarization), causing a drug-induced Long-QT syndrome (Compton et al., 1996; Huang et al., 2001; Roden et al., 1996; Splawski et al., 1997; Vandenberg et al., 2001). Drug-induced block of hERG1 and its associated prolongation of the QT interval and pro-arrhythmia has resulted in hERG1 being one of the most studied ion channels (Numaguchi et al., 2000; Sanguinetti, 2014; Witchel, 2011). Recent high-throughput screening studies have provided additional evidence for the central role of hERG1 blockade in drug safety assessments (Di Veroli et al., 2013b).

Despite of the plethora of experimental data available for drug interactions with hERG1 channel, *a-priori* prediction of the cardiotoxic potential for a novel compound during a pre-clinical developmental stage is a complex and a challenging task. The torsadogenicity is an emergent and a complicated property that depends on several factors: the conformational state of the channel being targeted by the compound (Chen et al., 2002; Lees-Miller et al., 2015; Stork et al., 2007; Wu et al., 2015); general kinetics of the drug access mechanisms (Di Veroli et al., 2013a; Guo et al., 2005; Hill et al., 2014); the solubility of the drug in the membrane (Wacker and Noskov, 2018); patient-to-patient variance in isoform composition of

hERG1 (hERG1a/hERG1b)(Sale et al., 2008) and isoform-specific interactions with blockers (Abi-Gerges et al., 2011). Given these factors, understanding molecular determinants of drug-induced QT-prolongation remains one of the fundamental and elusive problems in the field of molecular pharmacology. Even newly released “cardio-safe” drugs entering the market, such as ivabradine, are found to block the I_{Kr} , prolong action potential duration (APD) and can contribute to a potentially lethal drug-induced arrhythmia, known as Torsades de Pointes (TdP) (Chen et al., 2002; Duff et al., 1995; Lees-Miller et al., 2000; Lees-Miller et al., 2015; Melgari et al., 2015).

Ivabradine is commonly prescribed as a blocker of I_f (funny current) acting as a heart-rate lowering agent for symptomatic management of the chronic heart failure. However, over a similar range of concentrations, the drug also blocks hERG; thus, ivabradine prolongs Phase 3 of the action potential and has reported to induce TdP when applied in a poly-pharmaceutical context (Frommeyer et al., 2017; Hancox et al., 2015; Melgari et al., 2015). In the previous study, by combining electrophysiology and molecular modelling techniques, we emphasized the importance of the lipophilic interface and high-affinity state-dependent blockade of hERG1 by ivabradine (Lees-Miller et al., 2015). The molecular simulations performed on the homology model of hERG1 pore-domain in an open- and closed states indicated that ivabradine may bind to a lipid-facing binding pocket centered at the M651 residue (Lees-Miller et al., 2015). However at the time, findings were limiting due to the lack of structural information on the organization of the pore domain of the hERG1 channel. In 2017, a high-resolution Cryo-EM structure (3.4 Å) of a highly homologous neuronal hEAG1 channel has been resolved with a voltage-sensor in a depolarized (open) state, but with the closed pore domain. Later in the same year, high resolution structure of hERG1 channel (3.2 Å) was reported in the open state (Wang and MacKinnon, 2017; Whicher and MacKinnon, 2016) (Figure 1). These new structural atomic details provided the opportunity to unravel the potential lipophilic access mechanisms for the ivabradine-induced block of hERG1; to assess the impact of mutations at the M651 site in the distal S6 and to understand the dynamics of allosteric coupling between residues involved in the high-affinity channel block.

Herein, we report an in-depth study providing direct evidence that ivabradine interacts with lipid-facing residues in a state-dependent manner as part of the hERG1 blockade process. We assessed whether mutations of the lipid-facing residues while coupled with C-type inactivation impacting mutations affect the concentration of ivabradine required to block the hERG1 current. To reveal mechanisms involved in coupling- dynamics of the lipid-facing residues with respect to the aromatic cassette involved in high-affinity drug block by various compounds (Figures 1A-C), we performed several multi-microseconds Molecular Dynamics (MD) simulations of the WT- and mutated forms of hERG1 in conjunction with molecular biology and electrophysiological studies. The MD simulations in combination with the ensemble docking simulations allowed us to map molecular details of the probable lipophilic access pathway of ivabradine and potentially explain the drug's dependence on the inactivation process of hERG1 channel. Our results show that ivabradine's binding at the vicinity of the lipid-facing residue M651, is directly coupled to the conformational dynamics (re-orientation) of the aromatic cassette (F656 and F557) in the S6 (Figures 1A and 1B). Disruption of this allosteric coupling between drug binding on the lipid-facing surface and conformational dynamics of F656/F557 was shown to greatly attenuated ivabradine blockade.

MATERIALS AND METHODS

Molecular Biology

Methods for site-directed mutagenesis have been previously reported (Lees-Miller et al., 2015; Wang et al., 2016). The hERG1 constructs were transfected into mammalian hEK cells. Single- and double-mutants constructs of hERG1 were produced using conventional overlap PCR with primers synthesized by Sigma Genosys (Oakville, Ontario, Canada) and sequenced using Eurofins MWG Operon (Huntsville, AL). Constructs were linearized with *Xba*I restriction endonuclease and cRNA was transcribed *in vitro* using the mMessage mMachine T7 Ultra cRNA transcription kit (Ambion, Austin, TX).

General Setup for Electrophysiological recordings

The extracellular solution contained (in mM) NaCl 140, KCl 5.4, CaCl₂ 1, MgCl₂ 1, HEPES 5, glucose 5.5, the pH of the solution was adjusted and kept at 7.4 with NaOH. Micropipettes were pulled from borosilicate glass capillary tubes on a programmable horizontal puller (Sutter Instruments, Novato, CA). The pipette solution contained the following: 10 mM KCl, 110 mM K-aspartate, 5 mM MgCl₂, 5mM Na₂ATP, 10 mM EGTA - ethylene glycol-bis(-aminoethyl ether)-N,N,N,N tetraacetic acid, 5 mM HEPES, and 1mM CaCl₂. The solution was adjusted to pH 7.2 with KOH. Standard patch-clamp methods were used to measure the whole cell currents of hERG1 mutants expressed in HEK 293 cells using the AXOPATCH 200B amplifier (Axon Instruments)⁴. Unless otherwise indicated, the tail currents were recorded when the voltage was returned to -100 mV from +50 mV. Transfected HEK cells were patched to record the hERG1 currents⁴. Ivabradine was directly dissolved into the Tyrode solution right before the experiments. The solutions were used for the next two hours during the experiments. The stock solution of 100 μM ivabradine was prepared in the extracellular solution. Fresh stock solutions of ivabradine were prepared weekly.

Voltage-dependence of activation

From a holding potential of -80 mV cells were depolarized for 1 second to a range of voltages from -100 to +40 mV followed by a step to -100 mV (1 s) to record the tail currents. The isochronal tail current-voltage plots were fit to a single Boltzmann function (1):

$$\frac{I}{I_{max}} = \frac{1}{(1 + \exp[(V_{1/2} - V_m)/k])} \quad (1)$$

Where I/I_{max} is the normalized current, $V_{1/2}$ is voltage of the half-maximal activation, k is the slope factor and V_m is the membrane potential.

Analysis of Deactivation

Deactivation of hERG1 tail currents was measured by activating channels at +40, followed with a short (5 ms) repolarization step to -120 mV and deactivating step at -120, -100, -60 -40 mV. Currents at different voltages were normalized and fitted. The fitted data was averaged (n=10).

Statistical Analysis of Electrophysiological Experiments

Statsview (Abacus Concepts, Berkeley, CA) or QTI plot (Vasilef, 2013), Grace (<http://plasma-gate.weizmann.ac.il/Grace/>) were used to analyze the data. The null hypothesis of this study predicted no difference between the IC₅₀ values of the single to the double mutations assessed. The null hypothesis was rejected when the p value was <0.05 as evaluated by a One way Analysis of Variance with Tukey test. The exact p-values for data in Figure 4 are presented in the Supplemental Table 1. All variance measures (bars) for electrophysiological data are shown as Standard Deviation (SD). The study was exploratory, there was no *a priori* reason to consider whether there was an additive or subtractive interactions. In addition, we acknowledge that there may be other mutations, unknown to us at this time, which could be relevant. All of the comparisons were pre-specified and all of the comparisons are reported. *A priori*, we generally required a minimum of n=2 independent experiments for each point on the IC₅₀ curve. However, the *n* values near the IC₅₀ point and near the maximum blockade have a major impact on the reliability of the IC₅₀ estimate. Frequently we increased the *n* values at these putative points to be more certain about the reliability of the measurement. The *n* values for each point of the

concentration-response relationship are presented in the Figure legends. JG executed the experiments and analyzed the experimental data, hence he was not blinded. However, each experiment was reviewed by a small committee of individuals to assess quality of the records at weekly laboratory meetings (JG and HJD) and on a monthly basis (HJD and SYN) to review raw experimental.

Dofetilide and Ivabradine Water/Hexane Partitioning Experiments

The distribution coefficient for dofetilide and ivabradine were determined by the use of a classical shake-flask method detailed in our previous publications (Blokhina et al., 2016; Perlovich et al., 2006; Perlovichl and Bauer-Brandl, 2003). Prior to conducting the experiments, both solvents were mutually saturated to reach equilibrium point by slowly stirring them into a biphasic system for two days. In a separate study, ivabradine and dofetilide were dissolved in a pre-saturated hexane, following which the pre-saturated buffer at pH 7.4 was added. In order to ensure complete equilibration of the system as indicated by the absence of turbidity on each phase, the flasks were shaken for about 48 h in a thermostatic water bath at 293.15, 298.15, 303.15, 310.15 and 313.15 °K. After reaching the equilibration in the system, the samples from the lower phase were carefully removed with syringes for analysis. The molar concentrations of the dofetilide and ivabradine in the buffer phase were measured by a Cary-50 spectrophotometer (Varian, USA) with an accuracy of 2-4%. The experimental results are reported as an average value of at least three replicated experiments. The accuracy of the distribution coefficients were verified by comparing the starting mass of a compound and the total mass of the compound distributed in the two phases. The reproducibility of the measured concentrations was under 0.1%, and the maximum deviations from the average value were < 0.15%. The ratio of the compound equilibrium concentration in mole fraction in the hexane phase (x_H) to those in the aqueous phase (x_B) was determined using the hexane/buffer distribution coefficient in the following form:

$$D_{H/B} = x_H/x_B \quad (2)$$

$D_{H/B}$ is the phase equilibrium constant for a drug distributed in the hexane phase and the saturated buffer phase.

The standard Gibbs energy of transfer $\Delta_{tr}G^o$ from the buffer into an organic solvent was calculated by using:

$$\Delta_{tr}G^o = -RTD_{H/B} \quad (3)$$

The temperature dependence of distribution (van't Hoff method) was employed to obtain the enthalpy of transfer $\Delta_{tr}H^o$:

$$\frac{d(\ln D^*)}{dT} = \frac{\Delta_{tr}H^o}{RT^2} \quad (4)$$

The entropy of transfer $\Delta_{tr}S^o$ was calculated from:

$$\Delta_{tr}S^o = (\Delta_{tr}H^o - \Delta_{tr}G^o)/T \quad (5)$$

In-depth details on the partitioning experiments and quality controls are provided in the Supplemental Materials.

Molecular Dynamics Simulations

The 3D structure for the open state of the channel in this study is the recently published high-resolution cryo-EM structure of the trans-membrane domain of hERG1 channel (PDB ID 5VA2). The structure was truncated before the PAS and after CNBD domains as described in our previous publication (Perissinotti et al., 2018; Wacker et al., 2017). The 3D structure for the closed-state hERG1 channel is based on the homology modelling of hEAG1 with template derived from the cryo-EM structure (PDB ID 5K7L) solved at 3.78 Å resolution. The SWISS-MODEL program (Kopp & Schwede, 2004) was used to develop the hERG1 closed homology model from the available hEAG1 channel structure. Sequence alignment was performed using the CLUSTALW algorithm (Thompson et al., 1994). The sequence similarity between hERG1 and hEAG1 channels for the pore domain (S5-S6) is over 75 %.(Wacker et al., 2017). The detailed analysis of two structures was published recently (Vandenberg et al., 2017; Wacker et al., 2017). The main differences between pore domains of the two channels are located in the extended turret region connecting S5 to the pore helix. The following 3-step protocol was adapted to model missing

residues and flexible elements: (i) threading for generation of initial models based on template structure by copying coordinates over the aligned regions (for closed states), (ii) low-resolution ROSETTA loop modeling using Cyclic Coordinate Descent method (CCD), (iii) High-resolution all-atom refinement and selection of models based on ROSETTA clustering (Bender et al., 2016).

Models of the protein were generated from the alignment in a stepwise manner. CHARMM-GUI (Jo et al., 2008) was used to prepare protein - Dipalmitoylphosphatidylcholine (DPPC) lipid bilayer complexes solvated in 150 mM KCl aqueous solution using CHARMM-36 force field and TIP3P water model (Jorgensen et al., 1983; MacKerell et al., 1998; Noskov et al., 2004; Noskov & Roux, 2008; Klauda et al., 2010; Best et al., 2012). The fully assembled systems were equilibrated for 10 ns using NAMD2.10 (Phillips et al., 2005) and then subjected to production runs with ANTON2 super-computer. The production runs were performed for 1.0 to 2.5 μ s each with CHARMM36M (Huang et al., 2017) force-field to assess structural dynamics of residues involved in lipophilic access in hERG1 WT and selected mutants. The production runs were executing in a semi-isotropic (NP α T) ensemble at temperature 315 K maintained by the Nosé–Hoover thermostat (Martyna et al., 1994). The time step for production runs was set to 2 fs and trajectories were saved every 240 ps. Non-bonded and long-range electrostatic interactions were evaluated every 2 and 6 fs, respectively. Long-range electrostatics was calculated using the k-Gaussian Ewald method implemented to enhance performance on ANTON2 platform (Shan et al., 2005; Shaw, 2014) with a 64 Å \times 64 Å \times 64 Å grid. SHAKE was used to constrain all bonds involving hydrogen atoms. All of the subsequent trajectory analysis was performed using CHARMM c40b2 program package (Brooks et al., 2009).

Molecular Docking Protocols

Ivabradine in neutral and charged states was docked *in-silico* to the hERG1 open and closed pore structures in order to establish binding modes. This was performed via the Induced Fit Docking (IFD) approach available in the Schrödinger Suite. Schrödinger's IFD protocol uses Glide and Prime to exhaustively consider possible binding modes and the associated conformational changes within the

receptor's active sites. In addition to the well-established high-affinity binding pocket in the intra-cellular cavity of hERG1 channels, previous blinded docking studies revealed several alternative binding regions present in the hERG1 homology models and the Cryo-EM-derived structures (Lees-Miller et al., 2015; Saxena et al., 2016; Wacker et al., 2017). In order to map these alternative binding pockets as accurate as possible we have adapted the following two-step protocol. First, a blind docking was performed covering an entire receptor (e.g. PD and VSD regions of hERG1) and then elucidated common binding sites were selected for further studies with high precision grid mapping. The SiteMap module of the Schrödinger molecular modeling package was used to generate fine-grids for the subsequent precision docking. Following previously tested protocols, the grid was defined to 15 "site-points" for each pocket found during the blinded docking run. Then, crop site maps at 10 Å from the nearest site-point (Halgren, 2009). The scoring was carried out using Schrödinger's discretized version of the ChemScore empirical scoring function, resulting in the small number of the best-refined poses. Following which, the best-docked protein-ligand complex was determined based on a model energy score (E_{model}) that combines the energy of the grid-score, the binding affinity predicted by GlideScore, and (for flexible docking) the internal strain energy for the model potential used to direct the conformational-search algorithm. The partial charges for neutral form of the drug were based on the non-bonded parameters from the Optimized Potentials for Liquid Simulation Force Field (OPLS3) with parameters specifically optimized for drug-like molecules (Harder et al., 2016). The funnel width was increased by adjusting the energy window to 5.0, the CvdW cutoff was set to 10.0 kcal/mol, and the clustering criteria was set to 0.75 and XP (extra-precision) was used for all docking simulations (Friesner et al., 2006). In addition to single-structure docking procedure, MD-generated ensembles for the open hERG1 transmembrane (TM) and mutant forms were used in an ensemble docking with ivabradine to account for the conformational dynamics of the pore domain. Similar protocol was used in a comparative study of a cationic ivabradine binding to the main intra-cavitary site present in the open-state of hERG1.

Ensemble Docking Procedure

From the last 1.0 μ s of the production MD trajectories, we have randomly selected 25 frames spaced every 40 ns. The alignment of all frames was based on the positions of the backbone atoms from the pore domain (residues 545-572 and 635-669). Glide was used with the extra precision (XP) ensemble docking (Friesner et al., 2006) with Schrodinger Small-Molecule Drug Discovery Suite 2018-2 (2016) as described above for the single-structure docking protocol. The generation of the receptor grids is based on the ligand binding sites defined in a single-structure receptor docking. Each generated grid is made of two boxes: the inner box for searching docking space that defines acceptable volume for the ligand center to explore; and the outer box for searching the space of valid poses that must contain all ligand atoms in which grid potential are computed. The inner cubic box was fixed at the dimension of 15 Å×15 Å×15 Å while the outer box was set to 30 Å×30 Å×30 Å. The number of selected docking poses per docking simulation was set to ~ 50 and only poses with binding affinities of < -3 kcal/mol were clustered. It is important to mention that grids generated by the SiteMap protocol were overlapping. Therefore, poses obtained from separate docking simulations were clustered into 3 sites based on where the ligand was bound. First site corresponds to all of the poses found inside the intracellular cavity of the receptor (inside the cavity ~3 Å within of C α atoms of Y652 or F656); poses on the lipid facing transmembrane domain (lipophilic, within ~3 Å of of C α atom of M651) maps lipophilic site 2 and poses found between transmembrane segments of the pore domain (S5-S6) and the voltage sensing domain (S1-S4) map a putative “access path” site 3.

RESULTS

Rationale for the selection of mutants

Our previous *in-silico* screening of ivabradine binding to the hERG1 model representing open and closed states of the channel identified several potential binding modes (Lees-Miller et al., 2015). The best-scored binding poses for neutral and cationic ivabradine were clustered around a well-known intra-cavitary site in the open-state of hERG1, however, almost no binding in the internal cavity (Y652-F656) was observed for the closed state model. Two aromatic residues in the S6 helix lining the intra-cavitary site that are the most commonly associated with high-affinity blockade of hERG1 are Y652 and F656. Both residues are established as a critical determinant of hERG1 induced block-associated with pro-arrhythmia. (Ficker et al., 1998; Lees-Miller et al., 2000; Mitcheson et al., 2000; Perry et al., 2010). Recent work of Saxena et al. emphasized an important role of another aromatic residue (F557) from the S5 helix. It was shown that F557 may be involved in the drug stabilization of hERG1 binding pocket (Saxena et al., 2016) along with the residues in the S6 helix. Therefore, we chose to include F557X along with classic aromatic cassette Y652X and F656X to screen for ivabradine binding to the well-established intra-cellular site.

As for the M651 mutation, previous blinded docking studies showed a presence of a potential binding domain for ivabradine in close proximity to this residue, only in the open state of the channel (Lees-Miller et al., 2015). However, no electrophysiological experimental data on M651X mutants was reported in the previous manuscript. The MD simulations also showed a favorable energetic partitioning of the neutral state ivabradine into the lipid bilayers. The comparison of *in-silico* models used by Lees-Miller et al. (Lees-Miller et al., 2015) to the recently solved Cryo-EM structures showed that the key structural elements in the pore-domain (S5-S6) were accurately captured by ROSETTA-generated models of hERG1 (RMSD < 3.5 Å)(Wang et al., 2016) providing additional support of the docking studies on hERG1 models. In this study we created the M651T mutation to examine its effects on ivabradine binding (Figure 2). We reasoned that the substitution of methionine by the small polar amino acid (threonine) at the M651 site could disrupt the lipophilic binding or access route of ivabradine. We discovered that

M651T expressed well in cells but the mutation slowed deactivation kinetics of the channel and suppressed the block induced by ivabradine (Figure 2). This raised a possibility that M651T modifies ivabradine -induced block by altering the deactivation time-course of the channel. In order to account for this co-variable and to directly address whether the slowing of deactivation contributed to the shift in the concentration- response relationship to ivabradine, we created a double mutation, M651T/T618I. The rationale for creation of the double mutation M651T/T618I relates to a previous study wherein we reported that T618I accelerated deactivation kinetics. Thus, we empirically created the double mutation, M651T/T618I to restore deactivation to WT values, while retaining the key M651T substitution.

Mutations of lipid-facing residue M651 significantly alters thermodynamics and kinetics of ivabradine

Figures 2A and 2B show raw data of the concentration - dependent ivabradine induced block of WT hERG1 (Panel A) in comparison to the to M651T mutant (Panel B). Panel 2C shows a representative time-course of block of I_{hERG1} by ivabradine at various concentrations. Figure 2D shows the mean concentration-induced block comparing ivabradine (open circles for the WT, closed circles for the M651T) to dofetilide (open triangles, WT; and closed triangles, M651T; n values are shown in the legend). At 10 μ Mol/L ivabradine suppressed 75% of the WT current, whereas at the same concentration, the drug suppressed only blocked 10% of the M651T current (Figure 2, Panel D). The mean IC_{50} was 6.5 ± 10 μ Mol/L for ivabradine in WT (n=10), for M651T the IC_{50} was $> 120 \pm 10$ μ Mol/L (n=7), and beyond the drug's solubility limit. Note that to accurately measure IC_{50} , a concentration higher than its solubility limit is essential. The impact of the lipid facing residue M651 to ivabradine was also compared to dofetilide, a prototypic Class III antiarrhythmic drug to assess whether the mutant had a greater impact on response to ivabradine.

Interestingly, the M651T mutation had no impact on the concentration-response relationships to dofetilide. The mean IC_{50} concentration for dofetilide in WT was 41 nano-Molar (n=4) whereas it was

27 nano-Molar for the M651T mutation (n=5). Thus, the M651T alters the concentration-response relation for ivabradine but not for dofetilide.

The stark contrast in the drug sensitivity for a lipid-facing mutation suggests that these two drugs are accessing the main intra-cavitary site of hERG1 *via* different pathways. The pKa values reported for the strongest basic chemical moiety in ivabradine (9.37) is similar but somewhat lower than of dofetilide (9.6). Nonetheless, the cationic form of the drug is a dominant form in the bulk aqueous solution at the physiological pH values. However, the pKa values of weak-cationic compounds such as ivabradine is not the most accurate predictor of partitioning thermodynamics, since the equilibria between a neutral and a cationic form is a dynamic and environment-dependent process (DeMarco et al., 2018; Dickson et al., 2019).

To investigate thermodynamics of partitioning between aqueous phase and a model hydrophobic environment which mimics the membrane bilayer interior, we studied partitioning of ivabradine and dofetilide in an aqueous buffer and n-hexane. The thermodynamics of transfer for two drugs showed significant differences. The partitioning free energy data summarized in Table 1 directly demonstrate that ivabradine has nearly equal probabilities of partitioning between aqueous buffer and a bulk hexane (Table 1). The free energy of transfer (ΔG_{tr}^o) between aqueous phase and a bulk hexane for T=313.15° K are 0.5 ± 0.1 kJ mol⁻¹ and 8.4 ± 0.2 kJ mol⁻¹ for ivabradine and dofetilide, respectively. Therefore, partitioning data provide direct evidence that ivabradine is a lipophilic molecule, which partitions into the lipid compartment of the plasma membrane compared to dofetilide (Table 1). These findings are in excellent agreement with our previously published modelling studies (Lees-Miller et al., 2015).

While M651T Slows Deactivation its Impact on Ivabradine-Induced Block Appears Independent of Deactivation

In comparison to WT, M651T mutation slows deactivation; the *taus* of WT hERG1 was 160 ± 40 msec compared to 400 ± 40 msec in the mutant (p<0.01). Figure 2 Panels A, B and E show the raw deactivation time- course in response to ivabradine in WT (Panel A) and M651T (Panel B) and in a double mutation

which rescues deactivation to the WT values (Panel E). The M651T mutation (Panel B) shows the drug-free time-course of deactivation compared to the WT (Panel A). However, the double mutant channel, M651T/T618I restored the deactivation time-course of the channel to values similar to the WT hERG1 (compare Panels A, B and E); both drug-free and with ivabradine. Even the double mutant of hERG1 channel that contains M651T, still shifted the IC₅₀ concentration-response of ivabradine by >> 2 orders of magnitude (Figure 2, Panel F). The mean IC₅₀ values of M651T were nearly identical to that of the double mutation M651T/ T618I (Panel F). These data indicate: decreased pharmacological sensitivity to ivabradine was not due to the slowing deactivation kinetics induced by the M651T mutation.

Impact of other M651X substitutions on Ivabradine-Induced Block

The relationship between baseline drug-free electrophysiological characteristics and IC₅₀ values were evaluated by creating various substitutions at the M651 site (Supplemental Figures 1 to 4). We sought to address whether there was a relationship between electrophysiological characteristics and IC₅₀ response to ivabradine. We observed no significant correlation between drug-free voltage-dependence of activation ($V_{1/2}$), deactivation kinetics, or voltage-dependence of C-type inactivation and the concentration-responsiveness to ivabradine. However, there was a modest correlation between the drug-free time-constant of recovery from inactivation and the mean IC₅₀ values of ivabradine-induced block ($R^2=0.4$). We next examined effect of IC₅₀ concentration of ivabradine on ion currents elicited in various substitutions at the M651 site. The voltage-dependence of deactivation (during ivabradine treatment) and the kinetics of recovery from inactivation and their associated IC₅₀ values were significant but these correlations were quite modest. While many substitutions at this lipid-facing residue (Supplemental Table 2) have significant impact on responsiveness to ivabradine, correlation between “the lipophilicity of the residues” and the mean IC₅₀ values for ivabradine block was limiting or even absent ($R^2 < 0.1-0.4$). There were no apparent correlations between the IC₅₀ for ivabradine binding or volume or solvent-accessible area of the residues in the 651 position (Supplemental Figure 3). It is important to mention that in the

absence of ivabradine, several of the M651X mutants exhibited altered gating behavior (Supplemental Figures 3 and 4).

Therefore, ivabradine-induced block of hERG1 current could not be reduced to a simple drug binding in the vicinity of M651X. The drug action may be coupled to the gating process of the channel or altered accessibility to the intra-cellular cavity of the channel via some form of allosteric regulation. Essentially, drug-induced shifts in the time-course of recovery from inactivation appear to be a likely determinant of ivabradine potency. This coupling between presence of binding pockets, drug-channel interactions at the lipid-facing surface and gating dynamics is often described in terms of a complex allosteric mechanism where change in the topology of the binding pocket or inter-residue interactions modulates access or affinity for the substrate binding pocket (Gordon and Zagotta, 1995).

Temperature Dependence of Ivabradine blockade

The measured IC₅₀ values for ivabradine in WT hERG1 somewhat differ between various laboratories. We note that our originally published IC₅₀ value of 6.8 μMol/L differ from that of published by Melgari et al. (Melgari et al., 2015). The measurements performed by Melgari et al. were reported at 37° C whereas our measurements were made at 22° C. Accordingly, to address whether experimental conditions accounted for some of these differences in measured IC₅₀ values we directly compared IC₅₀ values of ivabradine at 37° versus 22° C. The measured wild-type IC₅₀ values at 37°C of 3.3 μMol/L is relatively close to the values of 2.07 μMol/L for hERG1 and 3.31 μMol/L for WT-hERG1 1a/1b isoform reported by Melgari et al (Melgari et al., 2015). Most importantly, we further re-establish that the impact of M651T was not significantly altered by increasing the temperature to 37°C. In fact, higher temperature may induce more potent block by ivabradine. The measured IC₅₀ of ivabradine decreases from 6.8 μMol/L to 3.3 μMol/L with an increase in temperature paralleling more favorable partitioning of ivabradine into the hexane at a higher temperature (Figure 3A/3B) (Table 1). Given that ivabradine is a highly lipophilic compound, the drug precipitates at higher concentrations as in these experiments. Thereby, making it

impossible to calculate an exceedingly accurate IC₅₀ value for ivabradine block of M651T because the solubility of ivabradine prevents evaluations at concentrations >100 μMol/L.

Interplay Between Aromatic Cassette (Y652, F656 and F557) Dynamics and Ivabradine-Induced Block

A vast number of studies describing molecular determinants of high- to mid-affinity blockade emphasized an important role played by aromatic residues in the pore domain cavity of the channel (Y652 and F656) (Duff et al., 1995; Lees-Miller et al., 2000; Lees-Miller et al., 2015) (Ficker et al., 1998; Lees-Miller et al., 2000; Mitcheson et al., 2000; Perry et al., 2010; Saxena et al., 2016). These residues are pivotal determinants of Class III drug- induced block of I_{hERG}; thus a range of double mutations were created to enhance our understanding of the interplay between those key residues in the pore domain and the lipid facing residue, M651 (Ficker et al., 1998; Lees-Miller et al., 2000; Mitcheson et al., 2000; Perry et al., 2010; Saxena et al., 2016). Figure 4 show the pharmacological responses of ivabradine to the single and double mutations. Figures 4A, B and C show the effects of adding the M651T mutation to F656C, Y652 or S620T. S620T is a mutant with impaired C-type inactivation phenotype (Herzberg et al., 1998) (Perry et al., 2007), which also has a major impact on channel induced activation or block by small molecules (Ficker et al., 1998; Herzberg et al., 1998; Wu et al., 2014; Wu et al., 2015). We have previously reported that the single mutation S620T decreases the pharmacologic responsiveness of I_{hERG1} to ivabradine (Lees-Miller; 2015).

A large concentration of ivabradine (100 micro-Molar) only partially blocks the F656C (72% block), Y652A (30%), M651T (30%) and S620T currents (32%), but almost no block was observed at the same concentration of ivabradine with either the M651T/F656C (<1% block); M651T/S620T (1% block); or M651/Y652A (12%) compared to their respective individual mutations as seen in Figure 4 (*p* and *n* values are shown in the legend and statistical analysis of the data is provided in the Supplemental Table 1). The analysis of electrophysiological recordings in Figure 4 show no additive or synergistic interplay between F656 and Y652 (Panel E). These data indicate that the M651 site substantially attenuates the

impact of known aromatic mutations in the distal S6. Mutations of F557L and M651T, both impaired ivabradine-induced block but surprisingly the block of the double mutant F557L/M651T was similar to the WT values (Figure 4, Panel D and the raw data are shown in Figure 5). These data indicate F557 in the S5 and M651 in the distal S6 negatively interplay to rescue pharmacologic response of ivabradine. However, no significant negative or positive interplay is observed with single or double mutations of F557L and S620T (Figure 4, Panel F). In review, the M651 residue interplays positively with many other key residues that are structural determinants of ivabradine-induced block. In contrast, M651T interplays negatively with F557L (Figure 5, Panel B). These data suggest a presence of a complex allosteric interaction of ivabradine with residues in hERG1 – a novel mechanism established in this work.

DISCUSSION

State-Dependence in the Ivabradine Blockade of hERG1 currents

One of the most important determinants of hERG1 block-associated pro-arrhythmia is the state-dependent kinetics of drug interactions with the channel (Di Veroli et al., 2013a) (Di Veroli et al., 2013b) (Hill et al., 2014). The land-mark feature of hERG1 channel kinetics is its rapid C-type inactivation (Sanguinetti et al., 1995; Schonherr and Heinemann, 1996; Spector et al., 1996). There are number of mutations that significantly alter or shift the voltage-dependence of C-type inactivation including S620T mutant. Therefore, the contribution of inactivation of M651T mutation on ivabradine-induced block was assessed by comparing the extent of block in M651T, S620T and the double mutant M651T/S620T. By combining a non-inactivating pore (S620T) with the M651T mutation, drug-block was virtually eliminated. These data indicate that both, the process of C-type inactivation and the M651 site in the distal S6, interact to produce at least additive impairment of ivabradine-induced block. Collectively, the results described for mutations in the positions F557, M651, Y652 and F656, indicate that drug blockade depends on the coupling between conformational dynamics of the residues in the pore domain and on mechanism that involve re-packing of the lipid- and/or pore-facing residues. How are state dependent conformational dynamics of F557, M651, Y652 and F656 coupled to drug access/binding to a pocket? In order to understand dynamics of these residues we performed 1.2 to 2.5 micro-seconds all-atom molecular dynamics (MD) simulations in an explicit water/membrane system for selected mutants.

Orientations of F557 and F656 are state-dependent properties: From pore-lining to lipid-facing

The availability of new Cryo-EM structures for hERG1 and hEAG1 channels in combination with recent developments in MD simulations allowed us to investigate structural dynamics of the open and closed states along with mutants of interest, hence directly allowing us to test the hypothesis presented above. In the previous and widely accepted mechanistic models, the aromatic residues (Y652 and F656) were postulated to face the permeation pathway and coordinate drugs bound to the intra-cellular cavity (Chen et al., 2002; Perry et al., 2010). Various structural models based on bacterial K⁺ channels or Shaker-

family of K⁺ channels emphasized the importance of direct interactions between drugs bound in the water-filled cavity with F656 and/or Y652 (Perry et al., 2010; Wacker et al., 2017). The recent progress in Cryo-EM technologies allowed us to model open- and closed-states of hERG1 channel. While hEAG1-based model represents a closed pore, a Cryo-EM structure for hERG1 corresponds to the open state. Importantly, spatial orientation of F656 and F557 side chains display remarkable state-dependence. As predicted by majority of structural modelling studies, the F656 is pointing towards the inside of the cavity in the closed state model (Wacker et al., 2017; Wang et al., 2016)). All-atom MD simulations indicate that F656 can rotate away from the permeation pathway and flickers in the open state model between the intracavitary and the lipid-facing orientations (Figures 6 Panels A to C). In the open state, the position of F656 aromatic ring is in the proximity of F557 and is close enough to form stable π - π stacking interactions at the lipophilic entry pathway.

In order to assess properties of the putative lipid-entry pathways and the impact of various mutations on the dynamics of F557-M651X-F656 motif, we performed topological analysis of the production portion of MD simulations (traces (Supplemental Figures 5 and 6) using MOLE online pathway analyzer (Berka et al., 2012). Two potential entry pathways were mapped from analysis of MD trajectories. Both pathways are defined by conformational states of F656 and F557 residues and illustrated in Figure 6 (Panel A). We analyzed the conformational dynamics of the F557-F656 pair to gain additional insight regarding the flexibility of a tentative lipid-facing binding site and its impact on the accessible volume required for drug diffusion into the primary intra-cavitary site (Supplemental Figure 5). The conformational space of F557-F656 interacting pair and the impact of M651T mutation in different states of hERG1 is illustrated in Figure 6 (Panels B, C, and D). The direct interactions between F656 and F557 appears to be only quasi-stable (flickering state) in the WT hERG1 (Figure 6, Panel B, C). This interactions establishes a large accessible volume for drug binding on the lipophilic site of the intracellular cavity. This interaction of the pair is state-dependent, which may directly support previously postulated role of F656 in the state-dependent drug blockade of hERG1 channel (Chen et al., 2002).

Therefore, it is tempting to assign the F656-F557 pair, a pivotal role in state-dependent gate control of ivabradine diffusion from the lipid bilayer to the main binding site in the intra-cellular cavity. The additional analysis of M651T mutant shows that the conformational flexibility of F656 and F557 pair is significantly impeded with the mutant (Figure 6, Panel C). Evidently, the M651T mutation significantly stabilizes the pair (F656 and F557) by decreasing the F656 “flickering” frequency (Figure 6, Panel B and C). Other mutations affecting conformational flexibility of F656 or F557 (Supplemental Figures 7 to 14) are also associated with inhibition of hERG1 blockade by ivabradine. The structural states of F656 appear to be important modulators of high-affinity binding for major hERG1 blockers (Supplemental Table 4 and Supplemental Figure 14).

In review, the state-dependent orientation of F656 appears to be an important determinant of a putative lipophilic entry pathway explored by some of the hERG1 blockers including ivabradine. The all-atom MD-refined models of hERG1 channel in its open and closed states demonstrate that F656 can rotate away from the intra-cellular cavity towards the lipid bilayer and form hydrophobic interactions with F557 and M651 residues (Figure 1). Interestingly, the conformational flexibility of F656 can be directly modulated by mutations in the position M651 or F557 is in excellent correlation with experimentally observed findings observed in ivabradine blockade to WT and mutant forms of hERG1.

Induced Fit Docking and MD-Ensemble Docking Supports Co-Existence of Binding Sites in the Pore Cavity and Pore-Lipid Interface

The extensive sampling of various conformational states of WT and mutant forms of hERG1 channel in different states achieved with ANTON2 platform allowed to map tentative binding sites for ivabradine. Potential binding sites around the mutated residues were explored through docking of ivabradine to different sections of the protein using hERG1 in different states, also incorporating ensemble docking, where cluster-representatives from all-atom MD simulations were utilized. Two main binding sites: “lipophilic site” and “internal cavity site” were further analyzed and compared for WT hERG1 and mutants. The stable and populated binding sites from induced-fit docking are shown in Figure 7, while

summary of docking energetics for all studied systems are shown in Tables 2 and 3. There were no poses found for ivabradine (either neutral or cationic form) binding to the main internal cavity of the hERG1 for the closed-state of the receptor (Table 2). For the closed-state of hERG1, ivabradine shows stable binding to the pocket centered at M651, in agreement with previously proposed lipophilic access site (Lees-Miller et al., 2015) (Table 2). In contrast to the closed state of the channel, the docking to the open state revealed three stable binding modes. Ivabradine was favorably bound: to the main pocket in the intra-cellular cavity, to an area around a fenestration window (in-between alpha helices of S6) or to a lipid-facing binding pocket (Figure 6 Panel A). The IFD docking performed to an open state of the hERG1 channel or the MD simulations to an ensemble of open structures show similar binding affinities for ivabradine (Table 3). The results of IFD docking qualitatively agrees with the experimental data (Table 2). At the same time, results from the MD-ensemble docking inherently have large uncertainties in computed binding affinities, rendering comparisons between mutants rather difficult (Table 3). However, the ensemble-based docking simulations allow for better quantification and comparison of relative populations found in each of the three binding sites. The population analysis is essential to understand binding processes that involve large and flexible ligands such as ivabradine (Shoichet and Kobilka, 2012; Zhao et al., 2010). The relative populations of binding poses found for identified sites are shown in Table 3 and Figure 7 (Panels A to C). Comparing number of poses from the docking simulations, ivabradine preferentially binds to the lipophilic site or the internal cavity of the WT hERG1. However, substantial number of poses are also found near a potential fenestration window or the “access pathway” (Figure 7, Panel A and Supplemental Figure 6).

For additional insights, we performed docking simulations on selected mutant systems, specifically M651T, F557L and F557L/M651T hERG1 mutants. It was found that in both M651T and F557L mutants, ivabradine showed a preferential binding to the IC cavity of the channel and a very small occupancy (number of poses) in the lipophilic binding pocket. In conclusion, ensemble docking for both mutants M651T and F557L, indicate disruption of the lipophilic access site due to the repacking of this binding

pocket caused by the mutations. The mutations in 651 and 557 reduced relative population of binding poses in the binding pocket near a potential fenestration window (access path to the internal cavity path) by two-fold compared to the WT system. These findings are in excellent agreement with the electrophysiological data presented herein. The data combined for the double mutant M651TF557L indicate almost WT-like binding affinities in all three mapped binding sites with modest increase in binding affinity for IC- and the access binding sites (Figure 7, Panel C). Therefore, the double mutant is expected to have WT-like binding properties in the open state of the channel. We conclude that flexible nature of F656 side-chain, which can rotate towards the lipid facing side and the internal cavity of the channel seems to be a determining factor of ivabradine-induced block. MD simulations have also showed that the double mutant (F557L/M651T) restores WT-like dynamics of F656 flickering, therefore re-establishing drug occupancy in the lipophilic and access site for ivabradine. Subsequent ivabradine docking to WT hERG1 and selected mutants (M651T, F557L and F557L/M651T) indicated that the lipophilic site is accessible to both open- and closed- states of the channel. However, the closed state of the channel contains no-binding pockets for ivabradine in the intra-cellular cavity and the “access” binding site near the fenestration window. The simulation data suggest that the structural re-arrangements of this binding pocket during channel’s activation may play a role in ivabradine binding to the lipophilic site and subsequent access to the entry site and ultimately into the intra-cellular cavity of the channel. Molecular docking simulations performed for the cationic form of ivabradine targeting primary site in the intracellular cavity show comparable binding free energies (to the lipophilic site) and also underline crucial role of F656 dynamics (Supplemental Table 4) coupled to the complex interactions with F557 and M651 residues.

CONCLUSIONS

In summary, we show that the pore-lipid interface mutation (M651T) significantly impairs ivabradine induced block of the hERG1 current but does not alter dofetilide induced block. Thus the impact of M651T appears to be specific to ivabradine and emphasizes the underlying important role of a new lipophilic access pathway. The structural mechanisms of the observed lipophilic binding of ivabradine were discerned from a combination of a micro-seconds long MD and traditional IFD/MD-ensemble docking simulations. The modelling data emphasize the role of M651 as an allosteric modulator of state-dependent hydrophobic interaction between F557 and F656, both of which are well-known determinants of ivabradine-induced block. The F557 residue was shown to interact with F656 by forming π - π stacking interactions; an interactions which is disrupted by M651. The overall process of M651 tugging on F656 results in a mobile and flickering F656, which flickers to face the lipid facing side and the internal cavity. Whereas M651T mutant is unable to interact with F656 which enhances F656 and F557 π - π stacking interactions, resulting in a rigid F656. Thus, M651 controls quasi-flickering state of F656 and shapes the topology of the binding pocket by controlling orientation of the F656/F557 hydrophobic cassette. MD simulations provide direct evidence that the mutations at these two position (F557 and M651) cause changes in the topology in the vicinity of the proposed access and/or lipophilic binding sites by altering F656 flexibility and rotations, thereby impacting number of binding pose and hence limiting the accessibility to the main binding pocket in the intra-cellular cavity of the open-hERG1. We conclude that in WT-hERG1 channel F656, M651, F557 residues act as a dynamic gate, which control pathway of drug access at the lipid facing domain into the intra-cellular cavity of the channel. The experimental data provided firm evidence that the extent of ivabradine blockade recorded for F557L/M651T mutant with WT-like conformational dynamics was essentially similar to the WT hERG1.

Acknowledgments

We would like to thank Drs. Marcela Madrid and Philip Blood of Pittsburgh Supercomputer Center for their valuable assistance with running molecular dynamics simulations on ANTON2 platform. We also would like to express our gratitude to Professor Martin Karplus and CHARMM project for waiving license fees for CHARMM program package used for analysis of simulation data.

There are no competing interests to declare.

Author Contributions

Participated in research design: LLP, JLM, JQ, SYN and HJD; *Conducted experiments:* JG LLP, MK, MO, AS, GLP; *Contributed reagents or analytical tools:* JG, HJD, BG, DM and SYN; *Performed data analysis:* LLP, JG JQ, MK, SYN and HJD; *Write or contributed to writing the manuscript:* LLP, JG, MK, BG, DM, SYN and HJD

References

- Abi-Gerges N, Holkham H, Jones EM, Pollard CE, Valentin JP and Robertson GA (2011) hERG subunit composition determines differential drug sensitivity. *Br J Pharmacol* **164**(2b): 419-432.
- Bender BJ, Cisneros A, 3rd, Duran AM, Finn JA, Fu D, Lokits AD, Mueller BK, Sangha AK, Sauer MF, Sevy AM, Sliwoski G, Sheehan JH, DiMaio F, Meiler J and Moretti R (2016) Protocols for Molecular Modeling with Rosetta3 and RosettaScripts. *Biochemistry* **55**(34): 4748-4763.
- Berka K, Hanak O, Sehnal D, Banas P, Navratilova V, Jaiswal D, Ionescu CM, Varekova RS, Koca J and Otyepka M (2012) MOLEonline 2.0: interactive web-based analysis of biomacromolecular channels. *Nucleic Acids Res* **40**(W1): W222-W227.
- Blokhina SV, Sharapova AV, O'khovich MV, Volkova TV and Perlovich GL (2016) Solubility, lipophilicity and membrane permeability of some fluoroquinolone antimicrobials. *Eur J Pharm Sci* **93**: 29-37.
- Brooks BR, Brooks CL, Mackerell AD, Nilsson L, Petrella RJ, Roux B, Won Y, Archontis G, Bartels C, Boresch S, Caflisch A, Caves L, Cui Q, Dinner AR, Feig M, Fischer S, Gao J, Hodoscek M, Im W, Kuczera K, Lazaridis T, Ma J, Ovchinnikov V, Paci E, Pastor RW, Post CB, Pu JZ, Schaefer M, Tidor B, Venable RM, Woodcock HL, Wu X, Yang W, York DM and Karplus M (2009) CHARMM: The Biomolecular Simulation Program. *J Comput Chem* **30**(10): 1545-1614.
- Chen J, Seebom G and Sanguinetti MC (2002) Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. *Proc Natl Acad Sci U S A* **99**(19): 12461-12466.
- Chiamvimonvat N, Chen-Izu Y, Clancy CE, Deschenes I, Dobrev D, Heijman J, Izu L, Qu Z, Ripplinger CM, Vandenberg JI, Weiss JN, Koren G, Banyasz T, Grandi E, Sanguinetti MC, Bers DM and Nerbonne JM (2017) Potassium currents in the heart: functional roles in repolarization, arrhythmia and therapeutics. *J Physiol* **595**(7): 2229-2252.
- Compton SJ, Lux RL, Ramsey MR, Strellich KR, Sanguinetti MC, Green LS, Keating MT and Mason JW (1996) Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. *Circulation* **94**(5): 1018-1022.
- DeMarco KR, Bekker S, Clancy CE, Noskov SY and Vorobyov I (2018) Digging into Lipid Membrane Permeation for Cardiac Ion Channel Blocker d-Sotalol with All-Atom Simulations. *Front Pharmacol* **9**.
- Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N and Boyett MR (2013a) hERG Inhibitors With Similar Potency But Different Binding Kinetics Do Not Pose the Same Proarrhythmic Risk: Implications for Drug Safety Assessment. *Journal of cardiovascular electrophysiology* **25**: 197-207.
- Di Veroli GY, Davies MR, Zhang H, Abi-Gerges N and Boyett MR (2013b) High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. *American journal of physiology Heart and circulatory physiology* **304**(1): H104-117.
- Dickson CJ, Hornak V, Bednarczyk D and Duca JS (2019) Using Membrane Partitioning Simulations To Predict Permeability of Forty-Nine Drug-Like Molecules. *Journal of Chemical Information and Modeling* **59**(1): 236-244.
- Duff HJ, Feng ZP and Sheldon RS (1995) High- and low-affinity sites for [3H]dofetilide binding to guinea pig myocytes. *Circ Res* **77**(4): 718-725.
- Ficker E, Jarolimek W, Kiehn J, Baumann A and Brown AM (1998) Molecular determinants of dofetilide block of HERG K⁺ channels. *Circ Res* **82**(3): 386-395.

- Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC and Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. *J Med Chem* **49**(21): 6177-6196.
- Frommeyer G, Weller J, Ellermann C, Kaese S, Kochhauser S, Lange PS, Decherer DG and Eckardt L (2017) Antiarrhythmic properties of ivabradine in an experimental model of Short-QT-Syndrome. *Clin Exp Pharmacol Physiol* **44**(9): 941-945.
- Gordon SE and Zagotta WN (1995) Localization of Regions Affecting an Allosteric Transition in Cyclic Nucleotide-Activated Channels. *Neuron* **14**(4): 857-864.
- Guo JQ, Zhan S, Lees-Miller JP, Teng GQ and Duff HJ (2005) Exaggerated block of hERG (KCNH2) and prolongation of action potential duration by erythromycin at temperatures between 37 degrees C and 42 degrees C. *Heart Rhythm* **2**(8): 860-866.
- Gustina AS and Trudeau MC (2009) A recombinant N-terminal domain fully restores deactivation gating in N-truncated and long QT syndrome mutant hERG potassium channels. *Proceedings of the National Academy of Sciences of the United States of America* **106**(31): 13082-13087.
- Halgren TA (2009) Identifying and Characterizing Binding Sites and Assessing Druggability. *Journal of Chemical Information and Modeling* **49**(2): 377-389.
- Hancox JC, Melgari D, Dempsey CE, Brack KE, Mitcheson J and Ng GA (2015) hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes. *Ther Adv Drug Saf* **6**(4): 177-179.
- Harder E, Damm W, Maple J, Wu CJ, Reboul M, Xiang JY, Wang LL, Lupyan D, Dahlgren MK, Knight JL, Kaus JW, Cerutti DS, Krilov G, Jorgensen WL, Abel R and Friesner RA (2016) OPLS3: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins. *J Chem Theory Comput* **12**(1): 281-296.
- Herzberg IM, Trudeau MC and Robertson GA (1998) Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels. *J Physiol-London* **511**(1): 3-14.
- Hill AP, Perrin MJ, Heide J, Campbell TJ, Mann SA and Vandenberg JI (2014) Kinetics of drug interaction with the Kv11.1 potassium channel. *Molecular pharmacology* **85**(5): 769-776.
- Huang FD, Chen J, Lin M, Keating MT and Sanguinetti MC (2001) Long-QT syndrome-associated missense mutations in the pore helix of the HERG potassium channel. *Circulation* **104**(9): 1071-1075.
- Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL, Grubmuller H and MacKerell AD (2017) CHARMM36m: an improved force field for folded and intrinsically disordered proteins. *Nat Methods* **14**(1): 71-73.
- Lees-Miller JP, Duan Y, Teng GQ and Duff HJ (2000) Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in *Xenopus* oocytes: involvement of S6 sites. *Molecular pharmacology* **57**(2): 367-374.
- Lees-Miller JP, Guo JQ, Wang YB, Perissinotti LL, Noskov SY and Duff HJ (2015) Ivabradine prolongs phase 3 of cardiac repolarization and blocks the hERG1 (KCNH2) current over a concentration-range overlapping with that required to block HCN4. *J Mol Cell Cardiol* **85**: 71-78.
- Martyna GJ, Tobias DJ and Klein ML (1994) Constant-Pressure Molecular-Dynamics Algorithms. *J Chem Phys* **101**(5): 4177-4189.
- Melgari D, Brack KE, Zhang C, Zhang Y, El Harchi A, Mitcheson JS, Dempsey CE, Ng GA and Hancox JC (2015) hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine. *J Am Heart Assoc* **4**(4).
- Mitcheson JS, Chen J, Lin M, Culberson C and Sanguinetti MC (2000) A structural basis for drug-induced long QT syndrome. *Proc Natl Acad Sci U S A* **97**(22): 12329-12333.

- Nerbonne JM and Kass RS (2005) Molecular physiology of cardiac repolarization. *Physiol Rev* **85**(4): 1205-1253.
- Numaguchi H, Mullins FM, Johnson JP, Jr., Johns DC, Po SS, Yang IC, Tomaselli GF and Balsler JR (2000) Probing the interaction between inactivation gating and Dd-sotalol block of HERG. *Circ Res* **87**(11): 1012-1018.
- Perissinotti L, De Biase P, Guo J, Yang P-C, Lee M, Clancy CE, Duff HJ and Noskov S (2018) Determinants of Isoform-Specific Gating Kinetics of hERG1 Channel: Combined Experimental and Simulation Study. *Frontiers in Physiology* **9**: 207.
- Perlovich GL, Volkova TV and Bauer-Brandl A (2006) Towards an understanding of the molecular mechanism of solvation of drug molecules: a thermodynamic approach by crystal lattice energy, sublimation, and solubility exemplified by paracetamol, acetanilide, and phenacetin. *J Pharm Sci* **95**(10): 2158-2169.
- Perlovich GL and Bauer-Brandl A (2003) Thermodynamics of solutions I: benzoic acid and acetylsalicylic acid as models for drug substances and the prediction of solubility. *Pharm Res* **20**(3): 471-478.
- Perry M, Sachse FB and Sanguinetti MC (2007) Structural basis of action for a human ether-a-go-go-related gene 1 potassium channel activator. *Proc Natl Acad Sci U S A* **104**(34): 13827-13832.
- Perry M, Sanguinetti M and Mitcheson J (2010) Revealing the structural basis of action of hERG potassium channel activators and blockers. *J Physiol* **588**(Pt 17): 3157-3167.
- Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J and Vincent GM (1996) Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. *Circulation* **94**(8): 1996-2012.
- Sale H, Wang J, O'Hara TJ, Tester DJ, Phartiyal P, He JQ, Rudy Y, Ackerman MJ and Robertson GA (2008) Physiological properties of hERG 1a/1b heteromeric currents and a hERG 1b-specific mutation associated with Long-QT syndrome. *Circ Res* **103**(7): e81-95.
- Sanguinetti M (2014) HERG1 channel agonists and cardiac arrhythmia. *Curr Opin Pharmacol* **15**: 22-27.
- Sanguinetti MC, Jiang C, Curran ME and Keating MT (1995) A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. *Cell* **81**: 299-307.
- Saxena P, Zangerl-Plessl EM, Linder T, Windisch A, Hohaus A, Timin E, Hering S and Stary-Weinzinger A (2016) New potential binding determinant for hERG channel inhibitors. *Sci Rep* **6**: 24182.
- Schönherr R and Heinemann SH (1996) Molecular determinants for activation and inactivation of HERG, a human inward rectifier potassium channel. *J Physiol* **493** (Pt 3): 635-642.
- Schrödinger L (2016) Schrödinger Suite 2018-2 Induced Fit Docking protocol; Glide, Schrödinger, LLC, Schrodinger LLC, New York.
- Shan YB, Klepeis JL, Eastwood MP, Dror RO and Shaw DE (2005) Gaussian split Ewald: A fast Ewald mesh method for molecular simulation. *J Chem Phys* **122**(5).
- Shaw DE, Grossman, J.P., Bank, J.A., Batson, B., Butts, J.A., Chao, J.C., Deneroff, M.M., Dror, R.O., Even, A., Fenton, C.H. and Forte, A (2014) Anton 2: Raising the Bar for Performance and Programmability in a Special-Purpose Molecular Dynamics Supercomputer. *IEEE Press*: 41-53.
- Shoichet BK and Kobilka BK (2012) Structure-based drug screening for G-protein-coupled receptors. *Trends Pharmacol Sci* **33**(5): 268-272.
- Spector PS, Curran ME, Zou AR and Sanguinetti MC (1996) Fast inactivation causes rectification of the I-Kr channel. *J Gen Physiol* **107**(5): 611-619.
- Splawski I, TristaniFirouzi M, Lehmann MH, Sanguinetti MC and Keating MT (1997) Mutations in the hminK gene cause long QT syndrome and suppress I-Ks function. *Nature Genetics* **17**(3): 338-340.

- Stork D, Timin EN, Berjukow S, Huber C, Hohaus A, Auer M and Hering S (2007) State dependent dissociation of HERG channel inhibitors. *Brit J Pharmacol* **151**(8): 1368-1376.
- Trudeau MC, Warmke JW, Ganetzky B and Robertson GA (1995) HERG, a human inward rectifier in the voltage-gated potassium channel family. *Science* **269**(5220): 92-95.
- Vandenberg JJ, Perozo E and Allen TW (2017) Towards a Structural View of Drug Binding to hERG K⁺ Channels. *Trends Pharmacol Sci* **38**(10): 899-907.
- Vandenberg JJ, Perry MD, Perrin MJ, Mann SA, Ke Y and Hill AP (2012) hERG K⁺ Channels: Structure, Function, and Clinical Significance. *Physiological Reviews* **92**(3): 1393-1478.
- Vandenberg JJ, Walker BD and Campbell TJ (2001) HERG K⁺ channels: friend and foe. *Trends Pharmacol Sci* **22**(5): 240-246.
- Vasilef I (2013) *Data Analysis and Scientific Visualization*. Universiteit Utrecht, Utrecht, Netherlands.
- Wacker S and Noskov SY (2018) Performance of Machine Learning Algorithms for Qualitative and Quantitative Prediction Drug Blockade of hERG1 channel. *Comput Toxicol* **6**: 55-63.
- Wacker S, Noskov SY and Perissinotti LL (2017) Computational Models for Understanding of Structure, Function and Pharmacology of the Cardiac Potassium Channel Kv11.1 (hERG). *Curr Top Med Chem* **17**(23): 2681-2702.
- Wang WW and MacKinnon R (2017) Cryo-EM Structure of the Open Human Ether-a-go-go-Related K⁺ Channel hERG. *Cell* **169**(3): 422-+.
- Wang YB, Guo JQ, Perissinotti LL, Lees-Miller J, Teng GQ, Durdagi S, Duff HJ and Noskov SY (2016) Role of the pH in state-dependent blockade of hERG currents. *Sci Rep-Uk* **6**.
- Whicher JR and MacKinnon R (2016) Structure of the voltage-gated K⁺ channel Eag1 reveals an alternative voltage sensing mechanism. *Science* **353**(6300): 664-669.
- Witchel HJ (2011) Drug-induced hERG Block and Long QT Syndrome. *Cardiovasc Ther* **29**(4): 251-259.
- Wu W, Gardner A and Sanguinetti MC (2014) Cooperative subunit interactions mediate fast C-type inactivation of hERG1 K⁺ channels. *J Physiol* **592**(20): 4465-4480.
- Wu W, Gardner A and Sanguinetti MC (2015) The Link between Inactivation and High-Affinity Block of hERG1 Channels. *Molecular pharmacology* **87**(6): 1042-1050.
- Zhao CF, Caplan DA and Noskov SY (2010) Evaluations of the Absolute and Relative Free Energies for Antidepressant Binding to the Amino Acid Membrane Transporter LeuT with Free Energy Simulations. *J Chem Theory Comput* **6**(6): 1900-1914.

Footnotes

This work was supported by the Canadian Institutes of Health Research Project Grant FRN-CIHR: 156236 (to JG, JLM and HJD.); the National Institutes of Health grant R01HL128537-01 (SYN, JG, LLP, and MK) and the Discovery grant from Natural Scientific and Engineering Research Council of Canada (to H.J.D). The computational support for this work was partially provided by West-Grid Canada through a resource allocation award to S.Y.N. MK was supported by Queen Elizabeth II graduate scholarship. Anton2 computer time was provided by the Pittsburgh Supercomputing Center (PSC - PSCA17021P award) through Grant R01GM116961 from the National Institutes of Health. The Anton 2 machine at PSC was generously made available by D.E. Shaw Research (Shaw, 2014).

Legends for Figures

Figure 1. Structural organization of drug binding site in the intra-cellular cavity of hERG1 channel. Panel A: Organization of the hERG1 pore-domain (two subunits are shown for clarity) in the open- (top) and closed- states (bottom), respectively. The location of key residues involved into the state-dependent dynamics of membrane-facing side windows is shown in a color-coded stick mode. **Panel B:** Access pathway to the intra-cellular cavity of hERG1 channel from the intra-cellular milieu. The differences in orientation of key hydrophobic residues involved to ivabradine-induced block are shown for the open- (top) and closed- (bottom) states, respectively. **Panel C:** illustrates trajectory-averaged iso-surfaces available for the drug lipophilic access to the intra-cellular cavity. The residue-based color coding was used to highlight protein-membrane interfaces present in the open- (top) and closed- (bottom) states of the channel, respectively.

Figure 2. Effect of Ivabradine on WT-hERG1 (Panel A) and M651T-hERG1 currents (Panel B), respectively. **Panel C:** The representative time-courses of the WT and M651T current in response to application of various concentrations of ivabradine. The original current traces at the times indicated with arrows were shown in Panels A and B.

Panel D: The dose-response curves of dofetilide (triangles) and ivabradine (circles) blockade of M651T-hERG1 (open symbols) and WT-hERG1 currents (solid symbols). The n=3, 6, 7 was used for all experiments with ivabradine blocking M651T-hERG1 in concentrations of drugs 1, 10 and 100 micM, respectively. For ivabradine block of WT-hERG1, n=5 was used for every concentrations. The dose-response curves of dofetilide block of M651T-hERG1 were obtained with n=5, 7, 5, 10 in the concentrations of 0.01, 0.03, 0.1 and 1 micM. For dofetilide block of WT-hERG1, n=1, 3, 2, 2, 5 in the concentrations of 0.002, 0.02, 0.1, 0.2, 2 micM were used. **Panel E:** Effect of ivabradine on M651T/T618I hERG1 currents. **Panel F:** The dose-response curves of ivabradine blockade of M651T/T618I hERG1 in comparison to blockade of M651T-hERG1. All experiments for M651T/T618I-hERG1 system were performed with n=3

Figure 3 The temperature dependence of the concentration -response curves for ivabradine blockade of WT-hERG1 (left panel) and M651T-hERG1 (right panel) currents at T=22 °C and 37 °C shown as closed- and open-circles, respectively. In the WT-hERG1 experiments at T=22 °C, n were 6, 5, 5, 5, 5 for the concentration of 1, 3, 10, 20, 100 micro-Molar of ivabradine. At T=37 °C, n= 8, 7, 3, 4 for drug concentrations of 1, 3, 10, 100 micro-Molar, respectively. In the M651T construct at T= 22 °C, n= 3, 6, 7 for experiments performed with 1, 10, 100 micro-Molar, respectively. At T= 37 °C n= 4, 3, 5 with 10, 30 and 100 micro-Molar, respectively.

Figure 4. Analysis of concomitant interactions of double mutations in blocking effects of saturating concentration of ivabradine (100 micM). Blocking effect of **Panel A:**M651T/F656C, **Panel B:** M651T/Y652A, **Panel C:** M651T/S620T, **Panel D:**M651T/F557L, **Panel E:**F656C/Y652A(E), **Panel F:**S620T/F557L and their corresponding single mutations where shown. The following number of experiments was used: N= 5, 7, 5, 4 in order of in panel A; 5, 7, 6, 3 in B; 5, 7, 5, 5 in C; 5, 7, 5, 5 in D; 5, 5, 6, 5 in E; 5, 5, 5, 4 in F. *: P<0.05; **: P<0.01. One way ANOVA analysis was used. The precise statistic P-values are provided in the Supplemental Table 1. WT was used as reference and was not included in the statistical analysis.

Figure 5. Current traces (**Panel A**) and time-course (**Panel C**) of ivabradine on M651T/F557L and their single mutations. **Panel C:** The concentration-response curves. The smooth curve was fitted to the Hill's equation. Fitting of M651T and F557L were not possible. The following numbers of experiments were performed: N=3, 4 & 5 in F557L; n=3, 6 & 7 in M651T; n=4, 5 & 5 in M651T/F557L in the concentrations of 1, 10 & 100 mM. **Panel D:** Patch clamp protocol.

Figure 6. Impact of the M651T mutation on the conformational dynamics of aromatic cassette in WT-hERG1 and M651T-hERG1 systems. The dihedral distributions and accessibility mapping were obtained from the last 750 ns of equilibrium all-atom MD simulations. **Panel A:** Side view of two subunits and top view of the pore domain showing relevant access pathways mapped by the MOLEOnline tool (see SI for details). Selected residues are shown: F557(green), F656 (magenta), M651 (orange) and Y652

(yellow). **Panel B:** Key distances and torsional angles involving F557 (green sticks) and F656 (magenta sticks). Position of residues M651 in the S6 helix are colored in orange. **Panel C:** Top- and side- views of the superimposed positions of F557 (green) and F656 (magenta) for WT-hERG1 (left) and M651T-hERG1 (right). **Panels D and E:** 1D and 2D distribution maps for torsional angles in each subunit of WT-hERG1 (**D**) and M651T (**E**). 1D distributions are shown for F557 (top panel) and F656 (side panel), respectively.

Figure 7. Molecular docking of ivabradine to different sites of the Pore Domain (PD) and the Trans-Membrane Domain (TMD). **Panel A:** Induced-Fit Docking (IFD) of ivabradine to PD access site (top), Lipophilic site (middle) and intra-cellular cavity site (bottom). Ivabradine is shown in magenta and relevant interacting residues are labeled. The arrows indicate the potential access route that the drug might follow to access the cavity and produce the block. **Panel B:** Ensemble of binding poses mapped from the IFD docking showing the exploration of the different binding sites for WT (top), M651T (middle) and F557LM651T (bottom) in the PD of hERG1. No poses were found in the access path site for M651T. **Panel C:** Group of poses found by MD-ensemble docking showing the exploration of the different binding sites for WT (top), M651T (middle) and F557LM651T (bottom) TM hERG1. Results involving only one of the four subunits are shown for clarity. Results for all subunits are displayed in the corresponding pie charts beside each system and in Table 3. In agreement with IDF docking performed with Cryo-EM structure, almost no poses were found on the access path site for M651T mutant.

Tables

Table 1. Mole fractions (x_S) and associated thermodynamic parameters for dofetilide and ivabradine hydrochloride partitioning in buffer-hexane system at T=298.15 and 313.15 K, pH=7.4 and pressure $p=0.1$ MP.

Temperature $^{\circ}K$	Buffer $x_B \cdot 10^6$	Hexane $x_H \cdot 10^6$	Log $D_{H/B}$	ΔG_{tr}° $\text{kJ} \cdot \text{mol}^{-1}$
Dofetilide				
313.15	5.38	0.215	-1.40	8.4 ± 0.2
298.15	5.34	0.258	-1.32	7.9 ± 0.2
Ivabradine				
313.15	3.55	2.93	-0.08	0.5 ± 0.1
298.15	3.69	1.67	-0.34	2.0 ± 0.1

Table 2. Binding affinities of ivabradine docking to hERG1 Pore Domain (PD) models (kcal/mol). Binding affinities of the best pose for WT and mutants are shown. Docking boxes were defined around the centroid of residues F557 and M651.

PD System	Closed hERG1Model		Open hERG1 Cryo-EM Model	
	20 Å Box BE (kcal/mol)		15 Å Box, BE (kcal/mol)	
	Lipophilic	Cavity	Lipophilic	Cavity
WT*	-5.45		-7.36	-8.59
F557L/M651T*	-5.05		-6.76	-8.89
M651T	-4.84	No Poses	-4.56	-7.95
F557L	-4.96		-5.44	-7.84

*Poses in the access path to internal cavity were found, see Figure 4, Supplemental Table 3 and Supplemental Figure 3.

Table 3: Ivabradine affinity to hERG1 transmembrane (TM) domain from GlideXP docking to the selected MD frames of WT and mutant hERG1. Poses were clustered into 3 binding sites: Cavity, Lipophilic and “access path”. Average energy considering all 4 subunits is presented as kcal/mol as well as the percentage of poses found within the binding site.

TM System	hERG1 Cryo-EM model		
	Cavity (kcal/mol)	Lipophilic (kcal/mol)	Access Path (kcal/mol)
WT	-5.22 ± 1.45 (43.2%)	-4.72 ± 0.93 (43.1%)	-4.42 ± 0.93 (13.7%)
M651T	-5.71 ± 1.31 (72.1%)	-4.58 ± 0.74 (25.3%)	-4.19 ± 1.40 (2.6%)
F557L	-5.57 ± 1.27 (67.2%)	-4.75 ± 0.89 (26.6%)	-4.27 ± 0.72 (6.1%)
F557L/M651T	-4.69 ± 1.10 (41.8%)	-4.76 ± 0.99 (27.3%)	-5.00 ± 1.08 (30.9%)

Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7

